Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - sitagliptin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and sitagliptin

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antinavikiniai vaistai - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

zentiva k.s. - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 25 mg - sitagliptin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 50 mg - sitagliptin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva gmbh - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin